Crit Care Med:红细胞输注对脓毒症患者有哪些不良影响?

2018-02-08 吴星 环球医学

2017年12月,发表于《Crit Care Med》上的一项使用边际结构Cox模型的观察性研究,考察了红细胞输注不会影响重度脓毒症患者的总体死亡率,但ICU获得性感染和严重低氧血症的发生率将增加。

2017年12月,发表于《Crit Care Med》上的一项使用边际结构Cox模型的观察性研究,考察了红细胞输注不会影响重度脓毒症患者的总体死亡率,但ICU获得性感染和严重低氧血症的发生率将增加。

目的:脓毒症患者常需要红细胞输注。然而,红细胞输注会带来不良事件,引起安全性担忧。一项随机对照试验确认了7g/dL的阈值,但是该试验排除了之前输注的患者。队列研究的结果具有争议,并未处理时间依赖性协变量和治疗史。因此,需要额外的数据来指导患者的管理

设计:为了评估1天内输注一次或更多次红细胞对30天时3个主要结局(死亡率、ICU获得性感染、严重低氧血症)的影响,研究者使用了边际结构模型。用基于红细胞比容变化的轨迹模型来识别亚组,并对每个亚组进行了二次分析。

地点:前瞻性法国多中心数据库。

患者:入院时具有脓毒症的患者。排除了出血性休克的患者。

干预:无。

测量和主要结果:总体来说,6016例患者队列中,输注红细胞与死亡不相关(风险比[HR] ,1.07;95%置信区间[CI] ,0.88~1.30;P=0.52)。然而,输注红细胞与ICU获得性感染(HR,2.77;95%CI,2.33~3.28;P<0.01)和严重低氧血症(HR,1.29;95%CI,1.14~1.47;P<0.01)发生率的增加相关。具有最低红细胞比容水平(26;四分位范围,24~28)的亚组,输注对死亡具有保护作用(HR,0.72;95%CI,0.55~0.95;P=0.02)。

结论:红细胞输注不会影响重度脓毒症患者的总体死亡率。ICU获得性感染和严重低氧血症发生率的增加是红细胞输注的预期结局,需要与其特定患者中的获益相权衡。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990028, encodeId=3c6519900286c, content=<a href='/topic/show?id=2d9fe718070' target=_blank style='color:#2F92EE;'>#红细胞输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77180, encryptionId=2d9fe718070, topicName=红细胞输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Aug 29 08:49:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281989, encodeId=e2ae1281989c8, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516360, encodeId=570015163604e, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608550, encodeId=f29e1608550f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286263, encodeId=fd2128626306, content=红细胞输注.不影响脓毒血症预后., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 08 16:07:02 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990028, encodeId=3c6519900286c, content=<a href='/topic/show?id=2d9fe718070' target=_blank style='color:#2F92EE;'>#红细胞输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77180, encryptionId=2d9fe718070, topicName=红细胞输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Aug 29 08:49:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281989, encodeId=e2ae1281989c8, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516360, encodeId=570015163604e, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608550, encodeId=f29e1608550f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286263, encodeId=fd2128626306, content=红细胞输注.不影响脓毒血症预后., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 08 16:07:02 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990028, encodeId=3c6519900286c, content=<a href='/topic/show?id=2d9fe718070' target=_blank style='color:#2F92EE;'>#红细胞输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77180, encryptionId=2d9fe718070, topicName=红细胞输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Aug 29 08:49:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281989, encodeId=e2ae1281989c8, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516360, encodeId=570015163604e, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608550, encodeId=f29e1608550f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286263, encodeId=fd2128626306, content=红细胞输注.不影响脓毒血症预后., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 08 16:07:02 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990028, encodeId=3c6519900286c, content=<a href='/topic/show?id=2d9fe718070' target=_blank style='color:#2F92EE;'>#红细胞输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77180, encryptionId=2d9fe718070, topicName=红细胞输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Aug 29 08:49:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281989, encodeId=e2ae1281989c8, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516360, encodeId=570015163604e, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608550, encodeId=f29e1608550f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286263, encodeId=fd2128626306, content=红细胞输注.不影响脓毒血症预后., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 08 16:07:02 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990028, encodeId=3c6519900286c, content=<a href='/topic/show?id=2d9fe718070' target=_blank style='color:#2F92EE;'>#红细胞输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77180, encryptionId=2d9fe718070, topicName=红细胞输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Aug 29 08:49:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281989, encodeId=e2ae1281989c8, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516360, encodeId=570015163604e, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608550, encodeId=f29e1608550f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 10 06:49:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286263, encodeId=fd2128626306, content=红细胞输注.不影响脓毒血症预后., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 08 16:07:02 CST 2018, time=2018-02-08, status=1, ipAttribution=)]
    2018-02-08 1e0f8808m18(暂无匿称)

    红细胞输注.不影响脓毒血症预后.

    0

相关资讯

Crit Care:美罗培南在脓毒症患者持续低效透析中的药代动力学研究!

近期,一项发表在杂志Crit Care上的研究旨在描述在接受持续低效透析(SLED)的重症患者中美罗培南的群体药代动力学(PK)。此项研究招募了19例接受美罗培南和SLED治疗的急性肾损伤败血症患者。在SLED之前、之中和之后,每个患者进行三次连续血液样品检测以评估美罗培南浓度。使用蒙特卡洛模拟的非参数群体进行PK分析。使用最小抑菌浓度(f T> MIC)的40%和100%时间的药效学(PD

NEJM:脓毒症休克患者激素辅助治疗

研究认为对于接受机械通气的脓毒性休克患者,氢化可的松不能显著降低患者死亡风险,但可以减少住院、休克及ICU治疗时间

Lancet Infect Dis:抗假单胞菌β-内酰胺治疗脓毒症:延长输注vs短期输注

2018年1月,发表在《Lancet Infect Dis》上的一项系统评价和Meta分析,考察了延长vs短期静脉注射抗假单胞菌β-内酰胺在脓毒症患者中的有效性。

脓毒症液体治疗急诊专家共识

早期、及时的液体治疗或复苏和必要的血管活性药物使用是脓毒症和脓毒症休克积极治疗的基本措施。其中,液体治疗或复苏的目的是通过快速补充液体达到纠正血容量相对或绝对不足,保证正常的心输出量和器官血流灌注,保护脏器功能。目前,在脓毒症与脓毒症休克的液体治疗中,就液体种类、治疗或复苏时机的确定以及复苏目标等都还存在认识上的差异。基层医生对脓毒症患者的液体治疗或复苏的认知和重视程度也存在不足。为进一步指导急诊

Clin Infect Dis:革兰阴性菌感染的脓毒症患者:哪些因素能预测耐药性风险?

2017年发表在《Clin Infect Dis》的一项由美国科学家进行的研究,考察了在革兰阴性菌(GNB)引发血流感染的脓毒症患者中,哪些因素能预测哌拉西林-他佐巴坦(PT)、头孢吡肟(CE)和美罗培南(ME)的耐药性风险。

Lancet Respir Med:救护车上给予抗菌药物能延长脓毒症患者的生存期吗?

2017年发表于《Lancet Respir Med》的一项多中心、开放性、随机试验,考察了救护车中院前抗菌药物治疗对脓毒症患者的效果。